

# The Science and Mystery of CRPS

Stephen Bruehl, Ph.D.


Professor of Anesthesiology

Vanderbilt University Medical Center

Nashville, Tennessee, USA



# Natural History of CRPS



Adapted from: Bruehl (2015)

# Is There a “Test for CRPS”?

- 2018 review paper:
  - No definitive CRPS test
  - Multiple potentially useful biomarkers
- 2019 Valencia Meeting – Possible biomarkers:
  - Degradation of Bradykinin (inflammatory mediator)
  - Osteoprotegerin (bone turnover marker)
  - IgG and IgM (immune marker)
  - microRNAs (miR-223, miR-338, and miR-548d)
  - NOT cytokines, bone scan, sensory testing, etc.



# Who is At Risk for CRPS?

- “High CRPS risk” profile:
  - **High acute pain intensity following injury**
    - **Support from multiple prospective studies**
  - Female (3-4 times more common)
  - Middle-aged ( $\approx$ 50-70 years old)
  - Fracture (>40% of cases)




# Who is At Risk for CRPS?

- Psychological factors are not a consistent predictor
  - CRPS is not a “psychogenic” condition
  - Theoretical model for psych-CRPS links
- Multiple studies show emotional distress has a stronger impact on CRPS pain than in other chronic pain conditions
  - Reflects physiology
  - Does NOT indicate pain is “all in your head”



# CRPS Mechanisms Are Complex



**Big Question:**  
*Cause CRPS vs.  
Associated with CRPS?*


**Animal models can address causation (e.g., support for inflammatory factors)**

## QUESTION:


**Why is it so hard to make progress  
in treatment of CRPS?**




# Patient Meets Budapest Criteria...




# Patient Meets Budapest Criteria...



# Patient Meets Budapest Criteria...



# Patient Meets Budapest Criteria...



# Inflammatory and Immune Mechanisms



# Inflammation and CRPS

- Proinflammatory Cytokines and Neuropeptides
  - TNF-alpha, IL-1 beta, IL-2, IL-6
  - Substance P, calcitonin gene related peptide (CGRP), and bradykinin
  - Elevated in local blister fluid, circulating plasma, and cerebrospinal fluid in CRPS
  - Elevated in early CRPS, diminishes over first year
- Oxidative Stress (also can → inflammation)?
  - Animal model of CRPS-I (IR model)



# Immune System and CRPS

- Inflammation and immune system linked
- Autoimmune role suggested in CRPS
  - Anti-neuronal antibodies significantly elevated in 30 -40% of CRPS patients
  - Autoantibodies sensitize pain receptors
- “Passive transfer model” and IgG



# Immune System and CRPS

- Treatment Implications?
  - Plasma exchange?
  - IVIG?
  - Immune modulating drugs?
- Small studies show possible benefit
- Mycophenolate trial (Goebel et al., 2018)
  - Effective overall (with several dramatic responders)
  - BUT - 45% stopped taking drug due to side effects
  - Larger trial and related trials planned



# Genomics and CRPS



# Genomics of CRPS

- Genetics – Reflects the DNA we were born with and never changes.
  - Inherited variations in genes *may* increase CRPS risk
- Strongest support for genetic risk factors:
  - CRPS clusters within families
  - Genetic differences in the human leukocyte antigen (HLA) system (underlies the adaptive immune response)

# Genomics of CRPS

- Gene Expression – How genes are translated into forming the actual proteins in your body.
  - DNA → RNA → Proteins
  - If you have a DNA signature that increases or decreases CRPS risk, actual risk only changes if that gene is turned on or off.



# Genomics of CRPS

- Best evidence:
- Small study showing different gene expression in 4 CRPS patients compared to 5 non-pain controls
- Two of the top hits:
  - HLA gene (immune-related)
  - MMP9 gene (collagen-related)

# Genomics of CRPS

- **Epigenetics** – Factors that can alter gene expression
- **DNA Methylation** – Can occur through genetic factors or environmental exposure. Alters gene expression. *These changes can be inherited and can impact on health even though the inherited DNA profile is unchanged*



# Genomics of CRPS

- Best evidence:
- RSDSA-funded study of military traumatic limb injury patients (+amputation)
  - N = 9 with CRPS (Budapest criteria)
  - N = 38 with non-CRPS neuropathic pain
- 48 genetic locations between groups showed significant differences in methylation ( $p < .001$ ) despite similar pain intensity
- Replication for 7 of these methylation sites




# Genomics of CRPS

- Top 2 methylation sites were in the *COL11A1* and *HLA-DRB6* genes (both less methylation)
  - *HLA-DRB6* - immune-related
    - Same gene showed associations with CRPS in the only gene expression study
  - *COL11A1* - regulates collagen formation (e.g., skin)
    - The only gene expression study also showed collagen-related differences in CRPS



# Functional Enrichment Analysis



# Implications?

- Speculation:
  - HLA system involved in autoimmune diseases
  - Maybe differential DNA methylation influences risk for CRPS via HLA-mediated autoimmune mechanisms?
- Implications for treatment mechanisms



# CRPS Stages and Subtypes



# Are There Progressive Stages of CRPS?

- Early CRPS expert proposed 3 sequential stages with different symptom patterns that all CRPS patients move through
- Cluster Analysis (Pattern Recognition) Study:
  - NO sequential stages, but ID'd 3 CRPS subtypes:
    - Limited + mostly neuropathic pain/sensory symptoms
    - Limited + mostly vasomotor symptoms (skin color/temp)
    - Classic severe CRPS/RSD with a variety of symptoms
- Similar results in a large Dutch study




# CRPS Subtypes: Warm vs. Cold CRPS

- Budapest discussions
  - Warm vs. Cold CRPS Subtypes? “Unproven”
- Large clinical study of 152 acute and chronic CRPS patients followed over 3 months
- Cluster analysis (pattern recognition):
  - Warm CRPS = warm/red skin, sweaty, swelling
  - Cold CRPS = cool/blue skin, less swelling




# CRPS Subtypes: Warm vs. Cold CRPS



Warm = Acute  
Cold = Chronic

# CRPS Subtypes: Warm vs. Cold CRPS



Transition from warm to cold CRPS over time?

# Treatment Implications



# Drug Development Status

- Good News:
  - Orphan Condition status with FDA (and EMA)
  - Encourages drug development
- Bad News:
  - Multiple recent failed trials (1 still ongoing?)
  - Bisphosphonates, immune modulator



# CRPS Complexity: TX Implications

- Problems:
  - Trials enroll “all CRPS patients”
  - Multiple CRPS mechanisms, and may differ between patients and over time
  - May be CRPS subtypes that respond and others that don’t (efficacy obscured by inclusion criteria?)
    - Recent trial results support this
  - Barrier to more CRPS trials = \$\$\$\$



# Responses to Questions

**For comprehensive CRPS overview, see:**  
Bruehl S. Complex regional pain syndrome.  
*British Medical Journal*. 2015; 351: h2730.  
[available free online]



# Question

*Problem with the Budapest (IASP) Criteria – Sometimes I meet criteria and sometimes I don't. Aren't these criteria most appropriate only for an initial diagnosis [before treatment improves symptoms]?*

- Valencia meeting in September 2019
- New diagnostic category for ICD 11?:
  - **“CRPS with Remission of Some Features”**



# Question

*Physicians question spreading – any evidence?*

- Yes - it occurs, but unclear how often
- Little available research (biased?)
- Definition issue:
  - Real spread (Budapest criteria) vs. secondary myofascial pain vs. widespread pain (CS?)
- Some bilateral mechanism changes are noted even before spreading of symptoms



# Question

- Patterns of spread (descending frequency):
  - Mirror-image spread (e.g., left to right)
  - Upper to lower limb (and vice versa)
  - Diagonal spread
  - All 4 limbs
- Occurs on average 19 mo. after initial onset
- 37-91% of spreading cases occur after second injury



# Question

*Is CRPS in children different than CRPS in adults?  
Physicians seem to treat childhood CRPS as more  
of a psychological condition.*



# Question

*Any evidence that CRPS and Fibromyalgia are related?*

- “Central Sensitization Syndromes”
  - Fibromyalgia
  - IBS
  - Migraine
  - Bladder pain
  - Others



# Question

*CRPS and Gastrointestinal Symptoms – “It has been suggested that CRPS is ‘doing something’ to my vagus nerve which controls the digestive system. Is this possible?”*

- Heart rate variability studies:
  - Low vagal tone in CRPS (and most pain conditions)
  - Low vagal tone linked to digestive disorders
  - Address via abdominal breathing practice:
    - **Breath in to count of 4, breath out to count of 6**



# Question

*If CRPS occurs in the context of a nerve injury, and the nerve eventually regenerates, would CRPS be expected to improve?*


- Specific nerve symptoms would resolve (numbness, tingling)
- Complex CRPS mechanisms, nerve injury only a small part (initial trigger?)



# Question

*Is CRPS associated with sleep problems? Are there any ongoing studies?*

- Our study in chronic back pain patients:



# Question

*What should a newly diagnosed CRPS patient know about treatments?*

- Caveat....
- Nothing proven highly effective for CRPS patients across the board (no cure)
  - Not many good studies to show what works
- CRPS is complex → multidisciplinary treatment
- SNS blocks used but no prolonged benefits



# Question

- Best evidence for:
  - Antidepressant + Antiseizure medications
    - Low risk, moderately effective pain control options
    - Antidepressants improve sleep (= improved pain?)
  - Physical/Occupational Therapy and avoid disuse of affected limb in daily life
  - Corticosteroids (early CRPS only)
  - Stimulators: SCS and DRG (NOT first line TX)
  - Bisphosphonates?? (maybe early CRPS only)



# Question

- Ketamine infusion may be effective
  - For evidence, see: Connolly SB, Prager JP, Harden RN. A systematic review of ketamine for complex regional pain syndrome. *Pain Med.* 2015;16(5):943-969.
- May help even in chronic CRPS due to its mechanism of action (central sensitization)
- Any form of ketamine (e.g., even sublingual) might work if adequate blood levels can be achieved
- More intensive protocols (repetition) better?
  - Benefits for 12 weeks?
- Need to balance benefits with risks (cognitive, liver)



# Question

*Any information on low dose naltrexone?*

- No real clinical trials (one stuck in process)
- Small case report suggests may be effective
- Mechanism make sense
  - TLR4 receptor → microglial inflammation
- Reflects problem in CRPS literature: Many experimental therapies with little evidence
  - Potentially waste money on ineffective treatments



# Question

*Are opioid analgesics useful for CRPS?*

- One study in CRPS patients (negative results)
- Carefully weigh benefits vs. costs/risks
- Problem with “opioid-induced hyperalgesia”
  - Snake chasing tale (vicious cycle).....
- Daily diary study: opioids used for mood control as well as pain control
  - Better options for mood control?



# Question

*Could CRPS increase the risk of a “cytokine storm” if I am infected with COVID-19?*

- Possible, but hard to say for sure....

